Login to Your Account



Early Data Show Promise with Adaptimmune's T-Cell Platform

By Nuala Moran
Staff Writer

Wednesday, November 21, 2012
LONDON – Adaptimmune Ltd. has published the first clinical data on its genetically modified T-cell technology, saying infusion of the engineered cells is safe, well tolerated and leads to a high response rate in a high-risk multiple myeloma population.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription